Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

作者： J. R. Infante , G. S. Falchook , D. P. Lawrence , J. S. Weber , R. F. Kefford

DOI: 10.1200/JCO.2011.29.18_SUPPL.CRA8503

关键词: Cancer cell 、 Pharmacokinetics 、 Pharmacology 、 Dosing 、 Drug 、 Salivary duct carcinoma 、 MEK inhibitor 、 BRAF Inhibitor GSK2118436 、 Melanoma 、 Medicine

摘要: … There was no clinically meaningful DDI between GSK436 and GSK212 after … was dosed 75-150 mg BID in combination with GSK212 1.0, 1.5, 2.0 mg QD. The recommended dose was 2 …

nih.gov 本地加速

ascopubs.org 本地加速

sci-hub.st HTML 下载加速

参考文章(0)

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

来源期刊

我的账户

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

来源期刊

相似文章 10

我的账户